Meta-analysis of amantadine efficacy for improving preclinical research reliability
Philip Stanley PhD
Research Statistics, Pfizer Worldwide Research and Development, Cambridge, United Kingdom
Search for more papers by this authorElsa Y. Pioli PhD
Motac Neuroscience, Manchester, United Kingdom
Search for more papers by this authorRouba Kozak PhD
Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA
Present address for Rouba Kozak: Biogen, Cambridge, Massachusetts, USA
Search for more papers by this authorMichael Popiolek PhD
Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA
Present address Michael Popiolek: Sage Therapeutics, Cambridge, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Erwan Bezard PhD
Motac Neuroscience, Manchester, United Kingdom
Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France
Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des Maladies Neurodégénératives, Bordeaux, France
Correspondence to: Dr. Erwan Bezard, Institut des Maladies Neurodégénératives, Université de Bordeaux, CNRS UMR 5293, 146 rue Léo Saignat, 33076 Bordeaux, France; E-mail: [email protected]Search for more papers by this authorPhilip Stanley PhD
Research Statistics, Pfizer Worldwide Research and Development, Cambridge, United Kingdom
Search for more papers by this authorElsa Y. Pioli PhD
Motac Neuroscience, Manchester, United Kingdom
Search for more papers by this authorRouba Kozak PhD
Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA
Present address for Rouba Kozak: Biogen, Cambridge, Massachusetts, USA
Search for more papers by this authorMichael Popiolek PhD
Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, USA
Present address Michael Popiolek: Sage Therapeutics, Cambridge, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Erwan Bezard PhD
Motac Neuroscience, Manchester, United Kingdom
Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France
Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des Maladies Neurodégénératives, Bordeaux, France
Correspondence to: Dr. Erwan Bezard, Institut des Maladies Neurodégénératives, Université de Bordeaux, CNRS UMR 5293, 146 rue Léo Saignat, 33076 Bordeaux, France; E-mail: [email protected]Search for more papers by this authorFunding agencies: This work was supported by Pfizer Worldwide Research and Development, in part with a grant received from the Michael J. Fox Foundation.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site
| Filename | Description |
|---|---|
| mds27486-sup-0001-Supinfo1.pdf1 MB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015; 132: 96-168.
- 2Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov Disord 2012; 27: 1373-1378.
- 3Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002; 3: 574-579.
- 4Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004; 16: 110-123.
- 5Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002; 15: 120-132.
- 6Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl 3): S2-S41.
- 7Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-1326.
- 8Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010; 25: 1357-1363.
- 9Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 2014; 82: 300-307.
- 10Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015; 30: 788-795.
- 11Tison F, Keywood C, Wakefield M, et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2016; 31: 1373-1380.
- 12Tison F, Negre-Pages L, Meissner WG, et al. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Parkinsonism Relat Disord 2013; 19: 416-421.
- 13Bezard E, Pioli EY, Li Q, et al. The mGluR5 negative allosteric modulator Dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 2014; 29: 1074-1079.
- 14Higgins J. Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 2008; 37: 1158-1160.
- 15Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
- 16Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998; 14: 75-82.
- 17Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One 2010; 5: e15298.
- 18Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141-143.
